Search Results

You are looking at 71 - 80 of 1,396 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Robert I Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney S. Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick M. Lamonica, Susan Mandel, Stephanie Markovina, Bryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael Yeh, Carly J. Cassara, and Susan Darlow

Overview For the United States population, the lifetime risk of being diagnosed with thyroid carcinoma is 1.2%. 1 It is estimated that approximately 43,800 new cases of thyroid carcinoma will be diagnosed in the United States in 2022. 2 The

Full access

Liver-Directed Therapies for Hepatocellular Carcinoma

Cletus A. Arciero and Elin R. Sigurdson

The authors have received a grant of less than $10,000 from the Sanofi Medical Advisory Board. References 1. Thomas MB Zhu AX . Hepatocellular carcinoma: the need for progress . J Clin Oncol 2005 ; 23 : 2892 – 2899

Full access

Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation

Juan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, Ignacio Durán, Luis Beltrán, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Jesus García-Donas, and Cristina Rodríguez-Antona

Treatment of advanced renal cell carcinoma (RCC) has changed drastically in the past decade. The mTORC1 inhibitors, everolimus and temsirolimus (also known as rapalogs ), have been shown to be key drugs for use in first-line treatment 1 and

Full access

Transplantation for Hepatocellular Carcinoma and Cholangiocarcinoma

B. Daniel Campos and Jean F. Botha

Edited by Kerrin G. Robinson

for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults . Gut 2003 ; 52 ( Suppl III ): iii1 – iii8 . 3 Llovet JM Burroughs A Bruix J . Hepatocellular carcinoma . Lancet 2003 ; 362 : 1907 – 1917 . 4 Blum

Full access

The Changing Treatment Landscape for Metastatic Urothelial Carcinoma

Thomas W. Flaig

. Flaig acknowledged this news and described the systemic treatment options for first- and second-line metastatic urothelial bladder carcinoma ( Figure 1 ). In addition, Dr. Flaig compared the similarities and differences among new immunotherapy options

Full access

Ovarian Clear Cell Carcinoma in Cowden Syndrome

Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol, and Carole Corsini

patient first underwent laparoscopic left adnexectomy and left iliac adenopathy resection surgery. Histologic analysis revealed a 15-cm ovarian clear cell carcinoma (OCCC) with ruptured capsule associated with a 7-cm satellite nodule inside the mesosalpinx

Full access

Surgical Management of Upper Tract Transitional Cell Carcinoma

Alison M. Lake and William W. Roberts

-tract transitional-cell carcinoma . J Endourol 2005 ; 19 : 841 – 848 . 2. Chen GL Bagley DH . Ureteroscopic surgery for upper tract transitional cell carcinoma: complications and management . J Endourol 2001 ; 15 : 399 – 404 . 3. Kerbl K

Full access

Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer

Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow

(FIGO) staging system has its limitations, particularly in the setting of corpus-confined carcinoma. Because the current staging scheme applies uniformly to all cases, irrespective of staging adequacy or tumor type, clinical outcomes are highly variable

Full access

Selection of Patients with Hepatocellular Carcinoma for Sorafenib

Ghassan K. Abou-Alfa

Treatment of Unresectable Hepatocellular Carcinoma . Available at: . Accessed February 9, 2009 . 2 Llovet JM Ricci S Mazzaferro V . Sorafenib in advanced hepatocellular carcinoma . N

Full access

Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials

Omar Abdel-Rahman, Hatim Karachiwala, and Jacob C. Easaw

( identifiers: NCT01124786, NCT00844649), 2 included patients with advanced gastric cancer (NCT00290966, NCT00678535), 1 included patients with advanced hepatocellular carcinoma (HCC; NCT00699374), and 3 included patients with advanced